CTLA4 and melanoma: Recently, the role of soluble NKG2DLs as candidate predictive biomarkers of clinical outcome to immunotherapy has been confirmed in a cohort of N = 194 melanoma patients treated with anti-CTLA-4 or anti-PD-1 mAb monotherapy or their combinations [46].